Carolina Alquézar1, Ana de la Encarnación1, Fermín Moreno1, Adolfo López de Munain1, Ángeles Martín-Requero1. 1. From the Department of Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) Madrid (Alquézar, de la Encarnación, Martín-Requero); the Neuroscience Area-Instituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain (Moreno, López de Munain); the Department of Neurology, Hospital Donostia, San Sebastian, Spain (Moreno); the Department of Neurosciences, University of Basque Country, San Sebastian, Spain (López de Munain); the CIBER de Enfermedades Neurodegenerativas (CIBERNED) (López de Munain) and the CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain (Martín-Requero).
Abstract
BACKGROUND: Loss-of-function progranulin gene (GRN) mutations have been identified as the major cause of frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein 43 (TDP-43) pathology (frontotemporal lobar degeneration [FTLD]-TDP); however, little is known about the association between progranulin (PGRN) deficiency and neuronal loss in individuals with FTLD-TDP. Previously we reported enhanced proliferative activity associated with the activation of WNT5A/CDK6/pRb signalling in PGRN-deficient cells. The objective of this work was to elucidate the association between PGRN deficiency, WNT5A signalling and cell proliferation in immortalized lymphoblasts from carriers of the c.709-1G > A GRN mutation (asymptomatic and FTLD-TDP). METHODS: We assessed cell proliferation in carriers of the c.709-1G > A GRN gene mutation and controls without GRN mutation and without sign of neurologic degeneration by cell counting or using an MTT assay. We used a luciferase assay to measure the nuclear factor-κ (NF-κ) activity. We evaluated messenger RNA levels using quantitative real-time polymerase chain reaction and protein levels by immunoblotting. Co-immunoprecipitation was used to analyze the interaction between PGRN and its receptors. RESULTS: We enrolled 19 carriers of the GRN gene mutation and 10 controls in this study. The PGRN-deficient cells showed increased expression of WNT5A due to NF-κB signalling overactivation. We observed a competition between PGRN and tumour necrosis factor-α (TNF-α) for binding both TNF receptors (TNFR) I and II. Blocking NF-κB signalling using wedelolactone or specific antibodies against TNFRs inhibited WNT5A overexpression and proliferation of PGRN-deficient cells. Conversely, the activation of NF-κB signalling by TNF-α increased WNT5A-dependent proliferation of control cells. LIMITATIONS: All cell lines were derived from individuals harboring the same splicing GRN mutation. Nevertheless, most of the known GRN mutations lead to haploinsufficiency of the protein. CONCLUSION: Our results revealed an important role of NF-κB signalling in PGRN-associated FTLD-TDP and confirm that PGRN can bind to TNF-α receptors regulating the expression of WNT5A, suggesting novel targets for treatment of FTLD-TDP linked to GRN mutations.
BACKGROUND: Loss-of-function progranulin gene (GRN) mutations have been identified as the major cause of frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein 43 (TDP-43) pathology (frontotemporal lobar degeneration [FTLD]-TDP); however, little is known about the association between progranulin (PGRN) deficiency and neuronal loss in individuals with FTLD-TDP. Previously we reported enhanced proliferative activity associated with the activation of WNT5A/CDK6/pRb signalling in PGRN-deficient cells. The objective of this work was to elucidate the association between PGRN deficiency, WNT5A signalling and cell proliferation in immortalized lymphoblasts from carriers of the c.709-1G > A GRN mutation (asymptomatic and FTLD-TDP). METHODS: We assessed cell proliferation in carriers of the c.709-1G > A GRN gene mutation and controls without GRN mutation and without sign of neurologic degeneration by cell counting or using an MTT assay. We used a luciferase assay to measure the nuclear factor-κ (NF-κ) activity. We evaluated messenger RNA levels using quantitative real-time polymerase chain reaction and protein levels by immunoblotting. Co-immunoprecipitation was used to analyze the interaction between PGRN and its receptors. RESULTS: We enrolled 19 carriers of the GRN gene mutation and 10 controls in this study. The PGRN-deficient cells showed increased expression of WNT5A due to NF-κB signalling overactivation. We observed a competition between PGRN and tumour necrosis factor-α (TNF-α) for binding both TNF receptors (TNFR) I and II. Blocking NF-κB signalling using wedelolactone or specific antibodies against TNFRs inhibited WNT5A overexpression and proliferation of PGRN-deficient cells. Conversely, the activation of NF-κB signalling by TNF-α increased WNT5A-dependent proliferation of control cells. LIMITATIONS: All cell lines were derived from individuals harboring the same splicing GRN mutation. Nevertheless, most of the known GRN mutations lead to haploinsufficiency of the protein. CONCLUSION: Our results revealed an important role of NF-κB signalling in PGRN-associated FTLD-TDP and confirm that PGRN can bind to TNF-α receptors regulating the expression of WNT5A, suggesting novel targets for treatment of FTLD-TDP linked to GRN mutations.
Authors: Marc Cruts; Ilse Gijselinck; Julie van der Zee; Sebastiaan Engelborghs; Hans Wils; Daniel Pirici; Rosa Rademakers; Rik Vandenberghe; Bart Dermaut; Jean-Jacques Martin; Cornelia van Duijn; Karin Peeters; Raf Sciot; Patrick Santens; Tim De Pooter; Maria Mattheijssens; Marleen Van den Broeck; Ivy Cuijt; Krist'l Vennekens; Peter P De Deyn; Samir Kumar-Singh; Christine Van Broeckhoven Journal: Nature Date: 2006-07-16 Impact factor: 49.962
Authors: Yun Li; Jason A Chen; Renee L Sears; Fuying Gao; Eric D Klein; Anna Karydas; Michael D Geschwind; Howard J Rosen; Adam L Boxer; Weilong Guo; Matteo Pellegrini; Steve Horvath; Bruce L Miller; Daniel H Geschwind; Giovanni Coppola Journal: PLoS Genet Date: 2014-03-06 Impact factor: 5.917
Authors: Noemí Esteras; Carolina Alquézar; Ana de la Encarnación; Alberto Villarejo; Félix Bermejo-Pareja; Angeles Martín-Requero Journal: Alzheimers Res Ther Date: 2013-11-07 Impact factor: 6.982
Authors: Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer Journal: Dement Geriatr Cogn Disord Date: 2020-04-28 Impact factor: 2.959
Authors: Raphael Schneider; Paul McKeever; TaeHyung Kim; Caroline Graff; John Cornelis van Swieten; Anna Karydas; Adam Boxer; Howie Rosen; Bruce L Miller; Robert Laforce; Daniela Galimberti; Mario Masellis; Barbara Borroni; Zhaolei Zhang; Lorne Zinman; Jonathan Daniel Rohrer; Maria Carmela Tartaglia; Janice Robertson Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-06 Impact factor: 10.154